Edition:
United Kingdom

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,821.50GBp
20 Apr 2018
Change (% chg)

-153.50 (-3.86%)
Prev Close
3,975.00
Open
3,800.00
Day's High
3,946.00
Day's Low
3,744.00
Volume
9,676,315
Avg. Vol
3,686,053
52-wk High
5,021.00
52-wk Low
2,940.50

Latest Key Developments (Source: Significant Developments)

Shire Says Considering Position With Respect To Fourth Proposal From Takeda
Friday, 20 Apr 2018 

April 20 (Reuters) - Shire Plc ::SHIRE PLC - STATEMENT RE PROPOSAL FROM TAKEDA PHARMACEUTICAL COMPANY LIMITED ("TAKEDA").SHIRE PLC - BOARD OF SHIRE IS CONSIDERING ITS POSITION WITH RESPECT TO FOURTH PROPOSAL AND WILL ISSUE A FURTHER ANNOUNCEMENT IN DUE COURSE.SHIRE PLC - CONFIRMS IT HAS RECEIVED A FOURTH PROPOSAL FROM TAKEDA ON 20 APRIL 2018 REGARDING A POSSIBLE OFFER FOR COMPANY.  Full Article

Shire Rejects Third Proposal From Takeda To Buy Out Co
Thursday, 19 Apr 2018 

April 19 (Reuters) - Shire Plc ::NOTES ANNOUNCEMENT MADE BY TAKEDA.BOARD HAS SINCE RECEIVED TWO FURTHER PROPOSALS.SECOND PROPOSAL COMPRISED £28.75 PER SHARE IN NEW TAKEDA SHARES, TO BE LISTED IN JAPAN AND IN US; £16.75 PER SHARE IN CASH.SECOND DEAL PROPOSAL REPRESENTS A POTENTIAL VALUE OF £45.50 PER SHARE.SECOND DEAL PROPOSAL REPRESENTS A POTENTIAL VALUE OF APPROXIMATELY £43 BILLION FOR TOTAL ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.UNDER SECOND PROPOSAL, BASED ON TAKEDA'S CURRENT MARKET CAP, SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 51 PER CENT. OF ENLARGED TAKEDA.THIRD PROPOSAL ALSO COMPRISED £28.75 PER SHARE IN NEW TAKEDA SHARES, TO BE LISTED IN JAPAN AND IN US THROUGH AN ADR LISTING, AND £17.75 PER SHARE IN CASH.BASED ON TAKEDA'S CURRENT MARKET CAPITALISATION, UNDER THIRD PROPOSAL SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 51 PER CENT.BOARD MET AGAIN AND THOROUGHLY CONSIDERED THIRD PROPOSAL WITH ITS ADVISERS, UNANIMOUSLY REJECTED IT, CONCLUDING THAT IT CONTINUES TO SIGNIFICANTLY UNDERVALUE CO.THIRD PROPOSAL REPRESENTS POTENTIAL VALUE OF £46.50 PER SHARE, ABOUT £44 BILLION FOR TOTAL ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.SHIRE'S ADVISERS ENTERED INTO A DIALOGUE WITH TAKEDA'S ADVISERS TO DISCUSS WHETHER A FURTHER, MORE ATTRACTIVE, PROPOSAL MAY BE FORTHCOMING.  Full Article

Takeda Says Shire Rejected Revised Proposal of 46.50 Pounds Per Share
Thursday, 19 Apr 2018 

April 19 (Reuters) - TAKEDA PHARMACEUTICAL CO LTD::TAKEDA - TAKEDA WAS NOTIFIED THAT BOARD OF SHIRE HAD REJECTED ITS PROPOSAL .TAKEDA PHARMACEUTICAL CO LTD - TAKEDA STATEMENT REGARDING SHIRE PLC.TAKEDA PHARMACEUTICAL CO LTD - CONFIRMS THAT ON APRIL 12 IT MADE A REVISED PROPOSAL TO BOARD OF SHIRE.TAKEDA - DISCUSSIONS BETWEEN PARTIES REGARDING A POTENTIAL OFFER ARE ONGOING.TAKEDA PHARMACEUTICAL CO LTD - REVISED PROPOSAL TO BOARD OF SHIRE TO ACQUIRE SHARE CAPITAL OF SHIRE FOR A PRICE EQUIVALENT TO £46.50 PER SHARE.TAKEDA PHARMACEUTICAL CO LTD - REVISED PROPOSAL TO BOARD OF SHIRE COMPRISED OF £17.75 IN CASH (TO BE PAID IN US$) AND £28.75 OF NEW TAKEDA SHARES..TAKEDA - PROPOSAL DOES NOT CONSTITUTE AN OFFER OR IMPOSE ANY OBLIGATION ON TAKEDA TO MAKE AN OFFER, NOR DOES IT EVIDENCE A FIRM INTENTION TO MAKE AN OFFER.TAKEDA PHARMACEUTICAL CO LTD - TAKEDA INTENDS TO MAINTAIN ITS WELL-ESTABLISHED DIVIDEND POLICY AND INVESTMENT GRADE CREDIT RATING.TAKEDA - TAKEDA WAS SUBSEQUENTLY NOTIFIED THAT BOARD OF SHIRE HAD REJECTED ITS PROPOSAL.  Full Article

Shire Sells Oncology Business To Servier For $2.4 Billion
Monday, 16 Apr 2018 

April 16 (Reuters) - Shire PLC ::SHIRE ANNOUNCES SALE OF ONCOLOGY BUSINESS TO SERVIER FOR $2.4 BILLION.PORTFOLIO ALSO INCLUDES CALASPARGASE PEGOL (CAL-PEG).SERVIER HAS AGREED TO ACQUIRE SHIRE'S ONCOLOGY BUSINESS AND PAY TOTAL CONSIDERATION IN CASH, UPON COMPLETION.TRANSACTION HAS BEEN APPROVED BY BOARD OF DIRECTORS AND IS EXPECTED TO CLOSE IN SECOND OR Q3 OF 2018.PROCEEDS FROM TRANSACTION INCREASE OPTIONALITY AND BOARD WILL CONSIDER RETURNING PROCEEDS OF SALE TO SHAREHOLDERS THROUGH SHAREHOLDER-APPROVED SHARE BUYBACK AFTER CURRENT OFFER PERIOD.DEAL COVERS TRANSFER OF SHIRE'S ONCOLOGY BUSINESS INCLUDING IN-MARKET PRODUCTS ONCASPAR , EX-U.S. RIGHTS TO ONIVYDE.  Full Article

Shire ‍says EMA has validated its marketing authorization application for Lanadelumab
Thursday, 29 Mar 2018 

March 29 (Reuters) - Shire Plc ::‍ANNOUNCED EUROPEAN MEDICINES AGENCY HAS VALIDATED ITS MARKETING AUTHORIZATION APPLICATION FOR LANADELUMAB (SHP643)​.‍REPORTS THAT HEALTH CANADA HAS COMPLETED SCREENING AND ACCEPTED NEW DRUG SUBMISSION UNDER PRIORITY REVIEW FOR INVESTIGATIONAL COMPOUND​.‍HEALTH CANADA'S RECENT ACCEPTANCE OF LANADELUMAB NDS FOR PRIORITY REVIEW SHORTENS REVIEW TIMELINE FROM 300 TO 180 DAYS​.  Full Article

AB Biosciences And Shire Enter Into Agreement
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Shire Plc ::AB BIOSCIENCES AND SHIRE ENTER INTO AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF AB BIOSCIENCES' PRIM PROGRAM.SHIRE PLC - NO FURTHER TERMS OF AGREEMENT WERE DISCLOSED.SHIRE PLC - ‍AB BIOSCIENCES TO RECEIVE AN UPFRONT LICENSE FEE AND POTENTIAL RESEARCH, DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FROM SHIRE​.SHIRE PLC - SHIRE RECEIVES EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP AND COMMERCIALIZE PRIM PROGRAM.  Full Article

Shire Says Granted EU marketing Authorization For ADYNOVI For Adults And Adolescents With Hemophilia A
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Shire Plc ::SHIRE GRANTED EU MARKETING AUTHORIZATION FOR ADYNOVI [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A​.‍SHIRE IS NOW AUTHORIZED TO MARKET ADYNOVI IN 28 MEMBER STATES OF EUROPEAN UNION (EU), AS WELL AS IN ICELAND, LIECHTENSTEIN AND NORWAY​.  Full Article

Shire Says Xiidra Approved By Health Canada To Treat Signs And Symptoms Of Dry Eye Disease
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Shire Plc ::XIIDRA APPROVED BY HEALTH CANADA TO TREAT SIGNS AND SYMPTOMS OF DRY EYE DISEASE.XIIDRA WILL BE AVAILABLE FOR PATIENTS IN CANADA IN EARLY 2018..  Full Article

Shire Files For FDA Approval Of New Plasma Manufacturing Facility In Covington, Georgia
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Shire Plc ::SHIRE FILES FOR FDA APPROVAL OF A NEW PLASMA MANUFACTURING FACILITY IN COVINGTON, GEORGIA TO SUPPORT GROWING IMMUNOLOGY FRANCHISE.SHIRE PLC - ‍COMMERCIAL PRODUCTION EXPECTED TO BEGIN IN 2018​.SHIRE PLC - EXPECTS TO MAKE A SECOND SUBMISSION TO FDA IN 2018 FOR ITS ALBUMIN THERAPY.  Full Article

Shire Says ‍U.S. FDA Has Granted Marketing Clearance To myPKFiT
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Shire Plc ::‍U.S. FOOD AND DRUG ADMINISTRATION HAS GRANTED 510(K) MARKETING CLEARANCE TO MYPKFIT FOR ADVATE​.  Full Article

Deals of the day-Mergers and acquisitions

April 20 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday: ** Japan's Takeda Pharmaceutical nudged up its offer for Shire to 44.3 billion pounds ($62 billion) to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals. ** General Electric Co said it was still considering a potential breakup of the 126-year-old industrial conglomerate, but such a move was secondary to running its businesses bett